Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Empagliflozin ameliorates cardiac dysfunction in heart failure mice via regulating mitochondrial dynamics
Yi-Ting Lyu, Junyu Huo, Wanying Jiang, et al.
European Journal of Pharmacology (2023) Vol. 942, pp. 175531-175531
Closed Access | Times Cited: 18

Showing 18 citing articles:

Mitochondrial quality control in human health and disease
Bohao Liu, Chen-Zhen Xu, Yi Liu, et al.
Military Medical Research (2024) Vol. 11, Iss. 1
Open Access | Times Cited: 30
Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches
Tatjana Radosavljević, Milica Branković, Janko Samardžić, et al.
Antioxidants (2024) Vol. 13, Iss. 8, pp. 906-906
Open Access | Times Cited: 14
New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions
Kyriazoula Chatzianagnostou, Melania Gaggini, Adrian Suman Florentin, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6218-6218
Open Access | Times Cited: 9
Targeting mitochondrial quality control for diabetic cardiomyopathy: Therapeutic potential of hypoglycemic drugs
Yutong Zhou, Wendong Suo, Xinai Zhang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115669-115669
Open Access | Times Cited: 19
Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications
Zahra Vaziri, Kiarash Saleki, Cena Aram, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115686-115686
Open Access | Times Cited: 12
Chinese and western medicine treatment of myocardial fibrosis drugs
Yuxi Zhu, Fangmei Zhang, Zhongcheng Li, et al.
Frontiers in Cardiovascular Medicine (2025) Vol. 11
Open Access
Empagliflozin in diabetic cardiomyopathy: elucidating mechanisms, therapeutic potentials, and future directions
Aiswarya Jaiswal, Poonam Yadav, Pushkar Singh Rawat, et al.
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access
Mitochondrial Quality Control: A Promising Target of Traditional Chinese Medicine in the Treatment of Cardiovascular Disease
Deng Pan, Pengfei Chen, He Zhang, et al.
Pharmacological Research (2025), pp. 107712-107712
Open Access
Adenosine triphosphate-induced cell death in heart failure: Is there a link?
Jingjing Zhang, Lu Cheng, Qian Qiao, et al.
World Journal of Cardiology (2025) Vol. 17, Iss. 4
Closed Access
Deciphering the mitochondria-inflammation axis: Insights and therapeutic strategies for heart failure
Baile Zuo, Fan Xiu, Dawei Xu, et al.
International Immunopharmacology (2024) Vol. 139, pp. 112697-112697
Closed Access | Times Cited: 3
The Off-Target Cardioprotective Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors: An Overview
Loredana N. Ionică, Adina V. Lința, Alina D. Bătrîn, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7711-7711
Open Access | Times Cited: 2
Effects of empagliflozin on right ventricular adaptation to pressure overload
Julie Birkmose Axelsen, Anders Hammer Nielsen-Kudsk, Janne Schwab, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 6
Inhibition of OAT1/3 and CMPF uptake attenuates myocardial ischemia-induced chronic heart failure via decreasing fatty acid oxidation and the therapeutic effects of ruscogenin
Qiong Lai, Xiaozhou Zhu, Lu Zhang, et al.
Translational research (2023) Vol. 261, pp. 1-15
Closed Access | Times Cited: 5
The latest emerging drugs for the treatment of diabetic cardiomyopathy
Minghao Li, Lin Liu, Chunyu Zhang, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 6, pp. 641-654
Closed Access | Times Cited: 1
Empagliflozin, a sodium‐glucose cotransporter inhibitor enhancing mitochondrial action and cardioprotection in metabolic syndrome
Yunhao Li, Zhanming Zhang, Zheming Zhang, et al.
Journal of Cellular Physiology (2024) Vol. 239, Iss. 6
Closed Access
OPA1 mediates cardiac function and metabolism: in silico and in vivo evidence
Claire Fong-McMaster, Serena M. Pulente, Luke Kennedy, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: lessons from preclinical studies
Rayla Rodrigues Soares, Larissa Freitas Viggiani, Juliano Moreira Reis Filho, et al.
Chemico-Biological Interactions (2024) Vol. 403, pp. 111229-111229
Closed Access
Targeting mitochondrial transfer: a new horizon in cardiovascular disease treatment
Baile Zuo, Xiaoyan Li, Dawei Xu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access
Page 1

Scroll to top